ACUTA CAPITAL PARTNERS, LLC - Q2 2024 holdings

Add to watchlist

$119 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 33 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 75.0% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
OCUL BuyOCULAR THERAPEUTIX INC$18,954,529
-21.0%
2,771,130
+5.2%
15.96%
+2.5%
BuyENLIVEN THERAPEUTICS INC$9,294,202
+33.4%
397,698
+0.4%
7.83%
+73.0%
PCVX BuyVAXCYTE INC$8,336,304
+16.4%
110,400
+5.3%
7.02%
+50.9%
DYN BuyDYNE THERAPEUTICS INC$7,499,125
+43.2%
212,500
+15.2%
6.32%
+85.6%
BuyPRAXIS PRECISION MEDICINES I$6,800,866
-31.3%
164,431
+1.3%
5.73%
-11.0%
CRNX BuyCRINETICS PHARMACEUTICALS$6,052,965
+64.9%
135,141
+72.4%
5.10%
+113.8%
INSM BuyINSMED INC$4,830,700
+188.5%
72,100
+16.8%
4.07%
+273.9%
BuyTOURMALINE BIO INC$3,467,236
-42.0%
269,614
+3.3%
2.92%
-24.8%
AGIO BuyAGIOS PHARMA$3,393,544
+110.0%
78,700
+42.4%
2.86%
+172.2%
KURA BuyKURA ONCOLOGY INC. COMMON STOCK$3,356,170
+74.8%
163,000
+81.1%
2.83%
+126.7%
NewCORBUS PHARMACEUTICALS HOLDI$2,918,625–64,500
+100.0%
2.46%–
MREO BuyMEREO BIOPHARMA GROUP PL-ADRspon ads$2,437,200
+85.6%
677,000
+70.2%
2.05%
+140.7%
BuyARCELLX INC$2,329,018
-2.9%
42,200
+22.3%
1.96%
+25.8%
NewHELIX ACQUISITION CORP II$1,817,484–177,836
+100.0%
1.53%–
ARGX NewARGENX SEsponsored adr$1,720,160–4,000
+100.0%
1.45%–
TRVI NewTREVI THERAPEUTICS INC$774,800–260,000
+100.0%
0.65%–
CELC NewCELCUITY INC$737,100–45,000
+100.0%
0.62%–
PLRX NewPLIANT THERAPEUTICS INC$496,650–46,200
+100.0%
0.42%–
NewRAPPORT THERAPEUTICS INC$465,200–20,000
+100.0%
0.39%–
NewNEWAMSTERDAM PHARMA CO NVordinary shares$432,225–22,500
+100.0%
0.36%–
SVRA NewSAVARA INCput$100,750–250
+100.0%
0.08%–
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
IOVANCE BIOTHERAPEUTICS INC24Q1 202321.2%
KURA ONCOLOGY INC. COMMON STOCK20Q2 20248.1%
IRIDEX CORP20Q3 20198.1%
ARROWHEAD PHARMACEUTICALS INC20Q2 20237.9%
IMMUNOMEDICS INC19Q3 202020.6%
VERACYTE INC19Q3 201910.1%
APELLIS PHARMACEUTICALS INC18Q4 202318.4%
ASCENDIS PHARMA A S18Q2 20207.2%
XENON PHARMACEUTICALS INC18Q3 20224.6%
CAS MED SYS PAR $0.00418Q1 20196.4%

View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ACUTA CAPITAL PARTNERS, LLC Q2 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
BCLS Acquisition Corp.Sold outFebruary 14, 202300.0%
Jiya Acquisition Corp.Sold outFebruary 14, 202300.0%
VistaGen Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Larimar Therapeutics, Inc.Sold outFebruary 15, 202200.0%
CATALYST BIOSCIENCES, INC.Sold outFebruary 14, 202200.0%
Aadi Bioscience, Inc.September 07, 20211,529,4027.2%
Kadmon Holdings, Inc.February 14, 20207,373,3334.6%
IRIDEX CORPSold outNovember 13, 201900.0%
ASSEMBLY BIOSCIENCES, INC.February 14, 2019718,5002.8%
CAS MEDICAL SYSTEMS INCFebruary 14, 20195,263,50818.2%

View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.

Latest filings
TypeFiled
N-PX2024-08-30
13F-HR2024-08-14
13F-HR2024-05-15
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14

View ACUTA CAPITAL PARTNERS, LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Export ACUTA CAPITAL PARTNERS, LLC's holdings

CSVXLS